1. Liver Cancer. 2022 Oct 25;12(2):180-183. doi: 10.1159/000527250. eCollection 
2023 Jun.

Atezolizumab and Bevacizumab Combination Therapy and Sequential Conversion 
Hepatectomy for Advanced Fibrolamellar Hepatocellular Carcinoma Presenting 
Pseudoprogression.

Matsuki R(1), Okano N(2), Hasui N(1), Kawaguchi S(1), Momose H(1), Kitahama 
K(3), Nagahama K(3), Kogure M(1), Suzuki Y(1), Nagashima F(2), Shibahara J(3), 
Mori H(4), Sakamoto Y(1).

Author information:
(1)Department of Hepato-Biliary-Pancreatic Surgery, Kyorin University Hospital, 
Tokyo, Japan.
(2)Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, 
Japan.
(3)Department of Pathology, Kyorin University School of Medicine, Tokyo, Japan.
(4)Department of Hepatology and Gastroenterology, Kyorin University Faculty of 
Medicine, Tokyo, Japan.

DOI: 10.1159/000527250
PMCID: PMC10267524
PMID: 37325496

Conflict of interest statement: Naohiro Okano has received honoraria from Taiho 
Pharmaceutical, Eli Lilly Japan, Chugai Pharma, and Ono Pharmaceutical. Other 
authors declare no conflicts of interest associated with this manuscript.